Organon partners with De Novo

Published: 30-Apr-2001


Cambridge, UK-based De Novo Pharmaceuticals is entering into a collaboration with Organon under its drug design partnership programme. Organon has paid a technology access fee to provide research funding for 12 months, and will pay milestones on successful progression of compounds through the discovery and development programme. De Novo is to use its proprietary computer algorithms to provide novel, patentable small molecule leads to Organon.

You may also like